GlassScriptPhysician profile
Tania Gonzalez
NPI 1043577406
$3,007.75
in general payments reported to CMS, 2019-2025
19 companies · $657 in 2025
The $657 reported for 2025 was more than what 76% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $365 · 2022: $443 · 2023: $715 · 2024: $829 · 2025: $657.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,200.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,201.94 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $561.75 | 2021-2025 | |
| Lilly USA, LLC | $374.79 | 2021-2025 | Mounjaro, Zepbound, Trulicity |
| Abbott Laboratories | $117.69 | 2023-2025 | Freestyle Libre 3 |
| Stryker Corporation | $115.83 | 2021 | |
| Pfizer INC. | $108.99 | 2023-2024 | |
| Astrazeneca Pharmaceuticals LP | $98.15 | 2023-2025 | Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $72.98 | 2022-2023 | Xarelto |
| Takeda Pharmaceuticals U.S.A., INC. | $67.07 | 2024 | Gammagard |
| Astellas Pharma US INC | $64.83 | 2023-2025 | Veozah, Myrbetriq |
| Nevro Corp. | $40.08 | 2024 | Senza |
| Kowa Pharmaceuticals America, INC. | $34.79 | 2023 | Seglentis |
| Paratek Pharmaceuticals, INC. | $33.21 | 2022-2025 | Nuzyra |
| Glaxosmithkline, LLC. | $22.75 | 2023 | Shingrix, Trelegy Ellipta |
| Optinose US, INC. | $21.20 | 2022 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $21.17 | 2023 | Xifaxan |
| Averitas Pharma INC. | $20.51 | 2024 | Qutenza |
| Amgen INC. | $16.16 | 2024 | Otezla, Repatha |
| Dexcom, INC. | $13.86 | 2024 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tania Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.